TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

Leadership Transition - TransMedics Group, Inc. appointed Mr. Gerardo Hernandez as Chief Financial Officer effective December 2, 2024, succeeding Mr. Stephen Gordon [1] - Mr. Gordon will remain a non-executive employee until March 31, 2025, and will serve as a non-employee senior advisor until March 31, 2026 [1][4] Executive Background - Mr. Hernandez has over 25 years of experience in finance, primarily in healthcare and consumer packaged goods sectors [3] - He previously served as Vice President Finance at Alnylam Pharmaceuticals and held significant roles at Shire, including leading corporate FP&A during its acquisition by Takeda for $62 billion [3] Financial Outlook - TransMedics updated its 2024 revenue guidance to a range of $428 million to $432 million, indicating a year-over-year growth of 77% to 79% [5][4] Upcoming Events - The management team will participate in the Piper Sandler Conference on December 3, 2024, and the TransMedics Investor & Analyst Day on December 10, 2024 [2][8]